
GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe - businesswire.com/news/home/2… #genetherapy #biologics #rarediseases #executivepositions #LHON #Ophthalmology

A clinical-stage biotechnology company developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.

GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe - businesswire.com/news/home/2… #genetherapy #biologics #rarediseases #executivepositions #LHON #Ophthalmology

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection | Business Wire businesswire.com/news/home/2…

GenSight Biologics invite Julien Secheyron, « Patient N°15 » de la 1ère étude clinique de LUMEVOQ®, à venir présenter son livre « Vous ne verrez plus » businesswire.com/news/home/2…

GenSight Biologics reports second patient case showing significant visual recovery after GS030 optogenetic treatment in the PIONEER Phase I/II trial Patient video on vimeo.com/646472992 #Optogenetics #Ophthalmology #retinitis #blindness #AAO2021

GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022 | Business Wire businesswire.com/news/home/2…

GenSight Biologics Reports Cash Position as of September 30, 2021 and Provides Operational Update | Business Wire businesswire.com/news/home/2…

Investigators conducted an optogenetics vision restoration in a man with retinitis pigmentosa who had been blind for decades — here's what they've found: buff.ly/2XaoihT @UPMC @UniBasel_en @GenSightBio #Ophthalmology #GeneTherapy

Magali Taiel of @GenSightBio discusses LUMEVOQ #genetherapy for Leber hereditary optic neuropathy Watch: 👉 ow.ly/BesJ50Grzd9 👈 @alliancerm #CGMesa21 #ophthamology #RegenerativeMedicine

Dr Magali Taiel will present at @alliancerm Cell & Gene Meeting on the Mesa about LUMEVOQ® #genetherapy to treat #lhon #rarediseases #blindness under regulatory review #EMA for European #maa expected in H1 2022 #CGMesa21 #RegenerativeMedicine #retina #ophthalmology

@LandosBio’s LABP-104 gets Approved for #SLE #treatment. #NIH Grant of USD 3 million to @AmydisInc for exploring #ASYN. #USFDA Grant to @GenSightBio’ #GS030 for #RetinitisPigmentosa. For more details, visit https://t.co/f91pXepu5X. (2/2) #pharma #biotech #news #pharmanews

Fast track designation for @GenSightBio's gene therapy GS030 businesswire.com/news/home/2…

La start-up française @GenSightBio a mis au point une thérapie génique qui redonne leur autonomie aux patients atteints de la maladie de Leber, qui rend quasi-aveugle en quelques semaines nouvelobs.com/economie/20211… récit par @domnora

Investigators conducted an optogenetics vision restoration in a man with retinitis pigmentosa who had been blind for decades — here's what they've found: buff.ly/3DZIHHA @UPMC @UniBasel_en @GenSightBio #Ophthalmology #GeneTherapy

@GenSightBio announces that the peer reviewed journal International Ophthalmology Clinics has published a review of all current and past gene therapy trials for LHON. To read more, go to https://t.co/jAfkvEW3p7 #Clinicaltrials #LHON

Just published in the peer-reviewed International Ophthalmology Clinics - Bilateral treatment effect following unilateral injection of #genetherapy independently reported by three research groups - LUMEVOQ® for #LHON first #genetherapy requesting #maa #EMA journals.lww.com/internat-op…

Join us at Chardan 5th Annual Genetic Medicines Conference #ChardanGMConf #CGMC2021 @bernard_gilly to present on Monday Oct. 4, 2021 8.00am ET. Webcast of the fireside chat to be available at https://t.co/MSG5S0c5MY for 90 days #genetherapy #cellandgenetherapy #rarediseases #LHON